Transformative Technologies for Early Cancer Detection.

Identifying viral cancers
earlier than ever before.

Learn More

Improving patient outcomes through early cancer detection.

Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.

Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer.

Our Core Technology

Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.

Highly Sensitive Blood Tests

Early cancer diagnosis in the general asymptomatic population.

Transform Cancer Detection

Real-time monitoring of response in patients undergoing treatment.

Improve Patient Outcomes

Detection of cancer recurrence in patients in remission.